BACKGROUND: Since the mid-1990s, effective antiretroviral therapy (ART) regimens have improved in potency, tolerability, ease of use, and class diversity. We sought to examine trends in treatment initiation and resulting human immunodeficiency virus (HIV) virologic suppression in North America between 2001 and 2009, and demographic and geographic disparities in these outcomes. METHODS: We analyzed data on HIV-infected individuals newly clinically eligible for ART (ie, first reported CD4+ count<350 cells/µL or AIDS-defining illness, based on treatment guidelines during the study period) from 17 North American AIDS Cohort Collaboration on Research and Design cohorts. Outcomes included timely ART initiation (within 6 months of eligibility) and virologic suppression (≤500 copies/mL, within 1 year). We examined time trends and considered differences by geographic location, age, sex, transmission risk, race/ethnicity, CD4+ count, and viral load, and documented psychosocial barriers to ART initiation, including non-injection drug abuse, alcohol abuse, and mental illness. RESULTS: Among 10,692 HIV-infected individuals, the cumulative incidence of 6-month ART initiation increased from 51% in 2001 to 72% in 2009 (Ptrend<.001). The cumulative incidence of 1-year virologic suppression increased from 55% to 81%, and among ART initiators, from 84% to 93% (both Ptrend<.001). A greater number of psychosocial barriers were associated with decreased ART initiation, but not virologic suppression once ART was initiated. We found significant heterogeneity by state or province of residence (P<.001). CONCLUSIONS: In the last decade, timely ART initiation and virologic suppression have greatly improved in North America concurrent with the development of better-tolerated and more potent regimens, but significant barriers to treatment uptake remain, both at the individual level and systemwide.
BACKGROUND: Since the mid-1990s, effective antiretroviral therapy (ART) regimens have improved in potency, tolerability, ease of use, and class diversity. We sought to examine trends in treatment initiation and resulting human immunodeficiency virus (HIV) virologic suppression in North America between 2001 and 2009, and demographic and geographic disparities in these outcomes. METHODS: We analyzed data on HIV-infected individuals newly clinically eligible for ART (ie, first reported CD4+ count<350 cells/µL or AIDS-defining illness, based on treatment guidelines during the study period) from 17 North American AIDS Cohort Collaboration on Research and Design cohorts. Outcomes included timely ART initiation (within 6 months of eligibility) and virologic suppression (≤500 copies/mL, within 1 year). We examined time trends and considered differences by geographic location, age, sex, transmission risk, race/ethnicity, CD4+ count, and viral load, and documented psychosocial barriers to ART initiation, including non-injection drug abuse, alcohol abuse, and mental illness. RESULTS: Among 10,692 HIV-infected individuals, the cumulative incidence of 6-month ART initiation increased from 51% in 2001 to 72% in 2009 (Ptrend<.001). The cumulative incidence of 1-year virologic suppression increased from 55% to 81%, and among ART initiators, from 84% to 93% (both Ptrend<.001). A greater number of psychosocial barriers were associated with decreased ART initiation, but not virologic suppression once ART was initiated. We found significant heterogeneity by state or province of residence (P<.001). CONCLUSIONS: In the last decade, timely ART initiation and virologic suppression have greatly improved in North America concurrent with the development of better-tolerated and more potent regimens, but significant barriers to treatment uptake remain, both at the individual level and systemwide.
Authors: Scott E Hadland; M-J Milloy; Thomas Kerr; Ruth Zhang; Silvia Guillemi; Robert S Hogg; Julio S Montaner; Evan Wood Journal: AIDS Patient Care STDS Date: 2012-03-19 Impact factor: 5.078
Authors: Stephen J Gange; Mari M Kitahata; Michael S Saag; David R Bangsberg; Ronald J Bosch; John T Brooks; Liviana Calzavara; Steven G Deeks; Joseph J Eron; Kelly A Gebo; M John Gill; David W Haas; Robert S Hogg; Michael A Horberg; Lisa P Jacobson; Amy C Justice; Gregory D Kirk; Marina B Klein; Jeffrey N Martin; Rosemary G McKaig; Benigno Rodriguez; Sean B Rourke; Timothy R Sterling; Aimee M Freeman; Richard D Moore Journal: Int J Epidemiol Date: 2007-01-08 Impact factor: 7.196
Authors: Michael J Mugavero; Andrew O Westfall; Anne Zinski; Jessica Davila; Mari-Lynn Drainoni; Lytt I Gardner; Jeanne C Keruly; Faye Malitz; Gary Marks; Lisa Metsch; Tracey E Wilson; Thomas P Giordano Journal: J Acquir Immune Defic Syndr Date: 2012-12-15 Impact factor: 3.731
Authors: Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks Journal: Ann Intern Med Date: 2012-09-04 Impact factor: 25.391
Authors: Lauren E Cain; Roger Logan; James M Robins; Jonathan A C Sterne; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; Ard van Sighem; Frank de Wolf; Heiner C Bucher; Viktor von Wyl; Anna Esteve; Jordi Casabona; Julia del Amo; Santiago Moreno; Remonie Seng; Laurence Meyer; Santiago Perez-Hoyos; Roberto Muga; Sara Lodi; Emilie Lanoy; Dominique Costagliola; Miguel A Hernan Journal: Ann Intern Med Date: 2011-04-19 Impact factor: 25.391
Authors: Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow Journal: PLoS One Date: 2009-05-18 Impact factor: 3.240
Authors: Linda Beer; Heather Bradley; Christine L Mattson; Christopher H Johnson; Brooke Hoots; Roy L Shouse Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: Neela D Goswami; Jonathan Colasanti; Jonathan J Khoubian; Yijian Huang; Wendy S Armstrong; Carlos Del Rio Journal: J Int Assoc Provid AIDS Care Date: 2017-02-15
Authors: Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller Journal: Curr HIV/AIDS Rep Date: 2018-06 Impact factor: 5.071
Authors: Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Anne K Monroe; Lindsey P Happ; Nabil Rayeed; Yan Ma; Maria J Jaurretche; Arpi S Terzian; Kevin Trac; Michael A Horberg; Alan E Greenberg; Amanda D Castel Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079
Authors: April D Kimmel; Steven P Masiano; Rose S Bono; Erika G Martin; Faye Z Belgrave; Adaora A Adimora; Bassam Dahman; Hadiza Galadima; Lindsay M Sabik Journal: AIDS Care Date: 2018-05-30
Authors: Keri L Calkins; Catherine R Lesko; Geetanjali Chander; Richard D Moore; Bryan Lau Journal: J Acquir Immune Defic Syndr Date: 2018-03-01 Impact factor: 3.731
Authors: Henry Masur; John T Brooks; Constance A Benson; King K Holmes; Alice K Pau; Jonathan E Kaplan Journal: Clin Infect Dis Date: 2014-02-27 Impact factor: 9.079
Authors: Heather J Ribaudo; Kimberly Y Smith; Gregory K Robbins; Charles Flexner; Richard Haubrich; Yun Chen; Margaret A Fischl; Bruce R Schackman; Sharon A Riddler; Roy M Gulick Journal: Clin Infect Dis Date: 2013-09-17 Impact factor: 9.079